Interleukin-6-Signal Transducer and Activator of Transcription-3 Signaling Mediates Aortic Dissections Induced by Angiotensin II via the T-Helper Lymphocyte 17-Interleukin 17 Axis in C57BL/6 Mice
Ang II-induced cytokines play in this process of local vascular inflammation are not well understood. Interleukin-6 (IL-6) is the most highly upregulated cytokine in Ang II-stimulated vessels yet identified, 11, 12 and it has been identified as an independent biomarker of vascular atherosclerotic risk and aneurysmal rupture. 13, 14 IL-6 is a member of a superfamily of cardioactive cytokines, whose members include cardiotropin, interleukin-11 and -12, and granulocyte-colony stimulating factor that bind to unique α-receptors and whose actions are mediated through a common glycoprotein 130 signal transducer converging on the signal transducer and activator of transcription (STAT)-3. 15, 16 Cellular targets of IL-6 signaling include vascular smooth muscle cells, endothelial cells, and monocyte/macrophage populations. Recently, we demonstrated that IL-6 plays a major pathogenic role in aortic dissections induced by Ang II because its deficiency significantly blocked aortic dissections, monocyte infiltration, reactive oxygen species formation, and chemotactic cytokine amplification. 11 Although our findings suggest that IL-6 is necessary for macrophage activation in the early stages of vascular inflammation leading to aortic dissection, IL-6 lacks chemotactic activity, and therefore, its effects on monocyte recruitment have not been fully explained.
Earlier studies have linked vascular effects of Ang II as mediated by lymphocyte populations. 2, 17 Not only are T and B lymphocytes found in Ang II-induced vascular diseases, 18 but the effect of Ang II on hypertension, vasomotor dysfunction, oxidative stress, arteriolar thrombosis, and atherosclerosis is prevented with total T-lymphocyte deficiency in mice. 19, 20 These studies suggest that T lymphocytes may play a central role in vascular pathogenesis. More recently, the CD4 + T-helper (Th) subset characterized by interleukin 17A (IL-17A) secretion (Th17), a subset distinct from the polarized Th1, Th2, and regulatory T cell populations, has been implicated in Ang IIinduced atherosclerosis and vascular dysfunction in a hyperlipidemic background. [21] [22] [23] [24] [25] [26] The role of IL-17A/Th17 activation and the mechanism for their accumulation in the development and progression of aortic dissections are not known.
In this study, we explored the relationship of IL-6 signaling in the formation of the Th17 cell population and the pathogenic role of IL-17A in aortic dilation and dissections induced by Ang II. Our approach used Ang II challenge of normolipidemic mouse models 11 with IL-6 and IL-17A deficiencies to assess the rate of aortic dissection. To establish clinical relevance, we also examined Th17 recruitment in human ascending aortic dissections. Our results suggest that a major consequence of vascular IL-6 signaling is the STAT3-dependent formation and recruitment of Th17 lymphocytes. Th17, in turn, plays an important role in monocyte recruitment and aortic dissections.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

IL-6 Deficiency Reduced Aortic Dissections and Th17 Recruitment Induced by Ang II
We have previously reported that chronic subcutaneous infusion of Ang II (2500 ng/kg per minute) induced aortic dissections (defined as intramural hematoma in the suprarenal aorta) 17 in 35% to 50% of aged mice. 27 In this study, aortic hematomas/dissections were demonstrated with aortic ultrasonography and tissue histochemistry. In wild-type (WT) mice in the C57BL/6 background, histochemical analysis of cross sections in the suprarenal abdominal aorta consistently showed adventitial thickening and blood-filled false lumens located in the tunica adventitia in the Ang II-treated mice ( Figure I in the online only Data Supplement). Approximately 40% of Ang II-infused mice developed areas of focal hemorrhages, visualized as false lumens indicating aortic dissection. All mice that developed dissections maintained an aortic size 50% greater than control aortas.
We reproduced our earlier studies of Ang II infusions conducted in IL-6 −/− mice in the C57BL/6 background, where we observed a significantly reduced early incidence of aortic dissections after 7 days (31% in WT, n=16, versus 0% in IL-6 −/− , n=12, respectively; 7 days; P<0.05). This reduction in the incidence of dissections was not accounted for by changes in the systolic blood pressure of IL-6 −/− mice. 28 Here, Ang II induced a pressor effect of 30 mm Hg after 7 days in WT mice (from mean 102±3 mm Hg to a mean of 132±6 mm Hg; n=10; P=0.002; Figure II in the online only Data Supplement), which was not statistically different from the pressor response in IL-6 −/− mice of the same background (mean 103±4 mm Hg to 119±7 mm Hg; n=10; P=0.048).
Earlier studies have shown that Ang II induces Th17 recruitment in hyperlipidemic vascular tissues, a cell type mediating hypertension, endothelial dysfunction, and atherosclerosis in the apolipoprotein E-deficient background. 23, 24, 29 To establish whether Ang II induces Th17 cell recruitment into the aortic wall in normolipidemic mice, we measured the abundance of IL-17A mRNA in the aorta and found that it was increased 4-fold relative to sham-infused mice ( Figure 1A ; P<0.01). IL-17A-positive immunostaining was found in both the medial and adventitial layers ( Figure 1A ; P<0.01).
To confirm that Ang II induced the aortic accumulation of the Th17 cell population, we conducted flow cytometric analysis of the dissociated aortae staining for both CD4 and IL-17A. Ang II induced a significant 5-fold recruitment of the CD4 +
IL17
+ Th17 cell population ( Figure 1B ; P<0.01). The retinoic acid receptor-related orphan receptor (ROR)γ-T directs Th17 cell differentiation. 30 To further confirm recruitment of Th17 cells, we quantified CD4 Figure 1C ; P<0.05) was also observed in response to Ang II infusion.
We next tested whether local macrophage and T-lymphocyte recruitment were affected in the IL-6 −/− background. Flow cytometric staining of aortic CD11b + macrophages indicated that Ang II-induced macrophage recruitment was abolished in IL-6 −/− mice ( Figure 2A ). We also tested whether IL-6 deficiency affected expression of IL-17A. 
IL-17A Neutralization Reduced Aortic Inflammation and Dissections Induced by Ang II
Because IL-6 plays a pivotal role in Th17 differentiation, we hypothesized that the reduced inflammatory phenotype observed in Ang II-treated IL-6 −/− mice was attributable, at least in part, to decreased Th17 activation. To test the pathogenic role of IL-17A, we infused Ang II in mice treated with an IL-17A-neutralizing antibody (NAb) or an isotype control antibody. First, we confirmed by ELISA that the IL-17A NAb reduced IL-17A secretion from aortic explants in tissue culture ( Figure 3A) . We found that a 2-week IL-17A NAb treatment significantly reduced Ang II-induced aortic dissections ( Figure 3B ; 33% in Ang II plus isotype control antibody, n=12, versus 0% in Ang II plus IL-17A NAb, n=13; P<0.01). Also, IL-17A neutralization reduced aortic dilation ( Figure 3B ; P<0.05 at day 12) and reduced aortic adventitial thickening. IL-17A NAb also abolished Ang II-induced aortic Th17 recruitment ( Figure 3C ; 12% in isotype control antibody treatment versus 4% with IL-17A NAb treatment; P<0.05). Neutralization of IL-17A also reduced the aortic macrophage population ( Figure 3D and 3E), indicating that IL-17A plays a role upstream of macrophage recruitment in Ang II-induced inflammation.
IL17 has been implicated in the Ang II-induced pressor response because IL-17A deficiency blunts the increase in blood pressure from Ang II infusion. 29 To determine whether IL17A neutralization produced a similar confounding pressor effect, we measured systolic blood pressures. We observed that at both baseline and after Ang II infusion, pressor effects were indistinguishable in untreated WT mice versus the IL17A NAb-treated mice. The mean systolic blood pressures of untreated WT mice changed from 96±4 mm Hg to 121±4 mm Hg after Ang II treatment, whereas the mean systolic blood pressure of the IL17A NAb-treated mice changed from 106±2 mm Hg to 135±8 mm Hg ( Figure 3F ). The pairwise differences in baseline and Ang II-induced blood pressures were not significant by antibody treatment. These data indicate that the IL17 NAb reduction in aortic dissections was independent of the pressor response.
IL-17A Deficiency Blunted Inflammatory Responses and Aortic Dissections
We next used IL-17A-deficient mice to test the role of Th17 lymphocytes in Ang II-induced vascular inflammation and aortic dissection. We found that, compared with WT mice, agematched IL-17A −/− mice had a significantly lower incidence of Ang II-induced early (7 days) and late (14 days) aortic dissections ( Figure 4A ; 41% and 50% in C57BL/6 versus 0% ). To determine the pressor response of the IL-17A −/− mice, systolic blood pressure was monitored. Here, we observed that IL-17A −/− mice had reduced resting blood pressure compared with WT controls (92±2 versus 101±2 mm Hg; P=0.015) and demonstrated a weak pressor response after Ang II infusion (104±5 versus 120±4 mm Hg; P=ns); the mean systolic pressure of the Ang II-infused IL-17A −/− mice was lower than the mean pressure of Ang II-infused WT controls (P=0.04; Figure 4E ).
IL-6-STAT3 Signaling Mediated Ang IIInduced Th17 Lymphocyte Formation
IL-6 signaling via the glycoprotein 130 transducer activates intracellular signaling mediated by the STAT3 or nuclear factor-IL6 pathway. 16 Our previous work has shown that STAT3 is activated in aortic monocytes in a manner that is absolutely dependent on IL-6. 27 To test the role of IL-6-STAT3 signaling, we synthesized a peptide derivative of the STAT3 second helix, a domain that binds specifically with STAT3 but not with STAT1, 31 fused to penetratin, 32 that we and others have shown is a potent cell-permeant inhibitor of STAT3 action ( Figure IV in the online-only Data Supplement). 31, 33 We found that the subcutaneous infusion of penetratin-STAT3 inhibitory peptide significantly reduced Ang II-induced aortic suppressor of cytokine signaling-3 mRNA expression ( Figure 5A ) as well as the suprarenal aortic dilation in WT mice (1.38±0.2 mm in Ang II-treated versus 1.19±0.05 mm in Ang II+penetratin-STAT3 inhibitory peptide-treated mice; P<0.05; Figure 5B ). The effect of penetratin-STAT3 inhibitory peptide on the formation of Th17 lymphocytes was measured in splenic lymphocytes. Here, we observed that Ang II induced a dramatic formation of Th17 cells, where 22% of the splenic lymphocytes were CD4 + IL17 + Th17 lymphocytes, and this number was significantly reduced to 13% in the presence of the penetratin-STAT3 inhibitory peptide (P<0.05; Figure 5C ). Together, these data indicate that STAT3 is a critical intracellular signal for Ang II-induced Th17 formation. Previous work has shown that macrophages and T lymphocytes are present in human aortic aneurysms. 3 To determine whether aortic Th17 recruitment is increased in humans with thoracic aortic aneurysm and dissection, we quantified IL-17A expression using immunohistochemistry in thoracic aortic samples from patients with transforming growth factor (TGF)-β receptor mutation (TGFBR2 R460C). We observed IL-17A immunostaining predominantly at the media-adventitia border ( Figure 6A-6F) . Rarely, IL-17A immunostaining was observed in the medial or intimal layers. Compared with controls, ascending aortic samples from patients with type A dissections caused by TGFBR2 mutation showed significant enhancement in IL-17A-expressing cell recruitment (4±2 cells/ field versus 82±23 cells/field, control versus thoracic aortic aneurysm and dissection, respectively; P<0.01; Figure 6G ).
To confirm local accumulation of Th17 cells, total RNA was extracted from the same samples and subjected to quantitative reverse transcription polymerase chain reaction for human interleukin-17 mRNA. We observed a 2.8-fold increase in human interleukin-17 mRNA in thoracic aortic aneurysm and dissection samples relative to control (P<0.05; Figure 6H ). These results extend the pathophysiological relevance of our observations that IL-17A-expressing Th17 cells are recruited into the aortic wall and mediate aortic dissections in a mouse model by suggesting that Th17 cells may also be important contributors to human aortic aneurysms and dissections.
Ang II-Induced Aortic Dissections Independent of its Vasopressor Effects
Other laboratories have demonstrated that the acceleration of atherosclerosis and abdominal aortic aneurysms in Ang II-infused mice is independent of Ang II-mediated increase in blood pressure. 2, 14, 34 To extend these observations to Ang II-induced aortic dissections, we examined the effect of Ang II Right, aortic diameter was quantified at days 3, 8, and 12 for each treatment group. Circles, Ang II-and IL-17A NAb-treated mice; squares, Ang II-and ICAb-treated mice (*P<0.05). C, Flow cytometric analysis of aortic CD4-and IL-17A-positive T-helper (Th) 17 cells was performed, and number of double-positive cells was measured (n=5 in each group). D, Aortic sections were immunostained for macrophages using monocyte + macrophage antibody (MOMA)-2 antibodies. Representative images of each treatment group from 3 different experiments are shown; both images magnified at ×200. E, Quantification of aortic macrophages for each treatment condition. MOMA-2+ cells were quantified microscopically as cells/visual field at ×200 magnification (*P<0.05). F, Systolic blood pressure measurements, recorded with tail-cuff plethysmography, were not different between Ang II-and IL-17A NAb-treated mice at baseline or at 6 days of Ang II infusion (n=5 mice per group; *P<0.05).
on dissections in mice made normotensive using the vasodilator hydralazine. WT mice were treated with hydralazine (onlineonly Data Supplement Materials) before and throughout infusion with Ang II. Under these conditions, the hydralazine-treated mice did not exhibit an Ang II-induced pressor response (mean of 101±3 mm Hg to a mean of 96±5 mm Hg; P=ns; Figure 7) . However, 33% of the normotensive hydralazine-treated mice developed aortic dissections, which was similar to 45% incidence of dissection in mice that were made hypertensive with Ang II (P=ns; Figure 7B ). These data indicate that Ang II-induced aortic dissections are independent of the systolic pressor response.
Discussion
Ang II is a potent inducer of vascular inflammation, IL-6 production, and monocyte recruitment and activation. In this study, we have found that IL-6 signaling converges on the recruitment of Th17 cells, a cell type necessary for the development of Ang II-induced aortic inflammation and dissections via its involvement in macrophage recruitment to the aortic wall. This work extends our previous study that identified IL-6-STAT3 signaling in monocyte activation to macrophages by providing a unifying mechanistic pathway where monocyte/macrophage recruitment into the aortic wall is coordinated by CD4 + IL-17A + Th17 lymphocytes. To our knowledge, this is the first application of a genetic deletion of IL-17A in normolipidemic C57BL/6 mice to study the role of IL17A in aortic dissection and dilation induced by Ang II.
Lacking direct chemotactic activity, the role of IL-6 in mediating inflammation has been elusive. Previously, we demonstrated that IL-6 signaling in Ang II-stimulated vascular disease was mediated by macrophage activation, a process involving phospho-Tyr STAT3 formation, loss of F4/80 cell surface staining, and induction of matrix-modifying matrix metalloproteases. 12, 27 Interpreted together, these data indicate that IL-6 is locally produced in sufficient concentrations to induce intracellular signaling, which directly leads to monocyte to macrophage differentiation. Our results here are surprising because they suggest that a second major target of aortic IL-6 secretion is the naive Th0 lymphocyte population, which is stimulated toward Th17 differentiation. Our findings that significant induction of Th17 lymphocyte in the spleen of Ang II-infused animals suggest that Ang II signaling significantly alters the lymphocyte −/− at 7 days (n=2 in each group). E, Systolic blood pressure was measured via a noninvasive tail-cuff method in conscious WT (>4-month old) and IL-17 −/− mice (>8-month old) at baseline and at day 7 of Ang II infusion, as indicated. *P<0.05. ns indicates no significance. population systemically. We interpret our data to mean that IL-6 is a potent regulator of aortic IL-17A production: it mediates the differentiation of Th cells into IL-17-producing Th17 cells found in the aorta by stimulating STAT3 activity.
Our data suggest that IL-17A expression is largely dependent on IL-6 signaling. However, a small induction of IL17 remains in aortas of IL-6 −/− mice ( Figure 2B ). Although many studies have shown that IL-6 is required for T-cell lineage development into Th17 cells, some innate immune cells are not dependent on IL-6 induction of RORγt and IL-17. For example, subsets of γδT cells and invariant natural killer T cells that do not undergo T-cell receptor selection constitutively express RORγT and can preferentially develop into IL-17-producing cells. 35 Similarly, stimulation of γδT cells with IL-1β or interleukin-23 promotes IL-17 secretion and does not require IL-6. 36 Furthermore, analysis of human abdominal aortic aneurysmal tissue has indicated the presence of an oligoclonal population of γδT cells; these data suggest γδT cells are involved in aortic inflammation. 37 One possible explanation of our findings is that Ang II infusion also stimulates innate γδT and invariant natural killer T cells to produce IL-17A even in the absence of IL-6. This IL-6-independent induction of IL-17A production would lead to monocyte chemotaxis and may account for the delayed inflammation and dissection observed in IL-6-deficient mice.
Several recent studies have used hyperlipidemic apolipoprotein E-deficient mice to study the effect of total T-lymphocyte 38 or Th17 cell 26 deficiency on aneurysm formation. Although these studies indicated that total T-cell or Th17 deficiency was not sufficient to attenuate Ang II-induced aneurysm formation in apolipoprotein E-deficient mice after 28 days of Ang II infusion, our results clearly suggest that defects in Th17 development protect against early development of aortic dissection and dilation by reducing vascular leukocyte infiltration and cytokine/chemokine expression. In this setting, reduced leukocyte infiltration may result in fewer medial breaks, an initial precursor lesion that is followed by aortic dissection and later, aneurysm formation ( Figure I in the online-only Data Supplement). 17 Th17 cells have been implicated in the pathogenesis of autoimmune and inflammatory diseases 39 and more recently in cardiovascular disease. 40 Increased circulating Th17 cells and Th17 cell infiltration into the aorta are found in Ang II-induced hypertension, and IL-17A deficiency blunts these responses and prevents hypertension. 29 Our data indicate that Th17 cells are enriched in the medial-adventitial border of suprarenal aortas ( Figure 1A, bottom) , indicating their accumulation at the principal site of dissection in this model. Others have shown that Th17 cells, as well as IL-17 expression in atherosclerosis, are increased, and blockade of IL-17A reduced aortic macrophage infiltration, cytokine secretion, and atherosclerotic plaque formation. 24, 38 Our data are consistent with these observations, where we observe reduced monocytic chemotactic protein-1 expression in IL-17A-deficient mice. Interestingly, other studies have shown that IL-6 expression is itself induced by IL-17A and reduced by blockade of IL-17A signaling, 24 suggesting an auto-amplification loop where the proinflammatory effects of IL-6 are enhanced by activated Th17 cells. These studies highlight an important proinflammatory role for T cells, especially the Th17 subset, in vascular inflammation and dissection. Wild-type mice were infused for 7 days with PBS (sham; n=3), angiotensin II (Ang II; n=5), or Ang II+penetratin-STAT3 inhibitory peptide (pSTAT3ip; n=6). Both Ang II and pSTAT3ip were delivered subcutaneously by osmotic mini-pumps. A, Expression of aortic suppressor of cytokine signaling-3 (SOCS3) mRNA was measured by quantitative reverse transcription polymerase chain reaction (*P<0.05). B, Aortic ultrasonography was used to monitor the full diameter of the suprarenal segment of the aorta (*P<0.05). C, Quantification of Th17 splenic cell population was performed by flow cytometry (n=3 in each group; *P<0.05). IL-17 indicates interleukin-17A.
Our flow cytometry data suggest that CD4 + T cells are a primary source of IL-17A in aortic tissue, but there is a component of IL-17A that comes from CD4-negative cell types ( Figure 1B) . Although Th17 cells are classically the main producers of IL-17A, 41 other cells, such as γδT cells, 42 lymphoid tissue inducer-like cells, 43 and invariant natural killer T cells, 44 have also been shown to produce IL-17A. It is possible that Ang II stimulates IL-17A production in these cell types, in addition to CD4 + cells. Further work will be required to determine cell-specific contribution to IL-17A production and formation of aortic dissection.
Monocyte/macrophage recruitment and differentiation play key pathogenic roles in Ang II-induced aortic aneurysms. 45 Discussed above, IL-17A contributes to inflammatory processes by promoting monocyte chemotaxis, adhesion, and migration. Indeed, reduced monocyte recruitment is seen on neutralization of IL-17A ( Figure 3E ). It has been recently reported that IL-17 induces monocyte migration partially through monocytic chemotactic protein-1 induction, consistent with our results of reduced monocytic chemotactic protein-1 expression in IL-17A −/− mice ( Figure 4) . 46, 47 IL-17A treatment of aorta from atherosclerotic mice promoted aortic chemokine (C-X-C motif) ligand 1 expression and monocyte adhesion. 24 Together, these results highlight an important role of Th17/IL-17A in the pathogenesis of aortic inflammation by promoting cytokine production and monocyte recruitment.
Besides vascular inflammation, hypertension is another well-established propathogenic factor for many cardiovascular diseases, including aortic dissections. Furthermore, we and others have previously shown that 2500 ng/kg per minute dose of Ang II administered subcutaneously by osmotic mini-pump results in hypertension. 27 Many laboratories have also demonstrated that infusion of a lower dose of Ang II (1000 ng/kg per minute) than that used in our studies promotes abdominal aortic aneurysms, independent of hypertension in hypercholesterolemic mice. 14, 48 In this study, we examined the pressor effects of Ang II on IL-6 knockout mice. Interestingly, although Lee et al 28 reported that IL-6 mediates the pressor effect of Ang II, we observed a pressor effect in IL-6 −/− , which was not statistically different from that of WT mice ( Figure II in the onlineonly Data Supplement). These differences may be a result of strain effects or differences in Ang II dosing. Nevertheless, the Wild-type (WT) mice were infused with Ang II for 7 days in the absence or presence of hydralazine. A, Baseline and post-Ang II infusion systolic BPs were measured using the tail-cuff method. Black bars, Ang II-treated WT; gray bars, Ang II-and hydralazine-treated WT (n= 9 to 11 mice per group; **P<0.01). B, The percent of dissections in each group was determined at the end of the study. ns indicates no significance.
finding that Ang II induced similar pressor responses suggests that the permissive role of IL-6 in aortic dissections is largely independent of a blunted pressor effect.
Our study expands our understanding of the inflammatory process in aortic dissections by identifying Th17 cells as a central coordinator of aortic inflammation. Because IL-17A acts on vascular tissue and induces the production of proinflammatory cytokines and chemokines 23, 24, 49 and reactive oxygen species, 25 we hypothesized that IL-17A-expressing Th17 cells may mediate recruitment of leukocytes to sites of inflammation in the aorta. Vascular cells, including endothelial cells, 49 smooth muscle cells, 25 and monocytes, 22 express IL-17RA, the major component of the receptor complex for IL-17A and IL-17F. 50 Recent in vitro and in vivo studies suggest an important role of IL-17A in mediating monocyte chemotaxis in different systems. 22, 47 Patients with rheumatoid arthritis who were treated with IL-17A antibody showed inhibited monocyte chemotaxis. 46 LDL receptor deficient (Ldlr −/− ) mice with IL-17R signaling disruption in bone marrow-derived cells resulted in reduced IL-6 production and attenuated atherosclerosis. 21 Apolipoprotein E-deficient mice with IL-17RA deficiency demonstrated decreased production of proinflammatory cytokines/chemokine and reduced recruitment of macrophages, T cells, and neutrophils. 22 Consistent with these findings, our results indicate that abnormalities in Th17 activation caused by IL-17A deficiency or IL-6 deficiency lead to a reduction in macrophage recruitment and cytokine/chemokine expression in the wall of the aorta.
Previous work has shown that IL-17A-deficient mice have a blunted long-term pressor response to Ang II infusion. 29 In our studies, we surprisingly found IL17 NAb did not affect resting or pressor responses to Ang II; however, the IL-17A −/− mice had a reduced resting systolic blood pressure and a blunted Ang II pressor response. These divergent observations on the pressor responses may suggest that there may be developmental role of IL17A on vascular tone in IL17 −/− mice that is not apparent with short-term IL17 neutralization. Furthermore, the divergent observations on the pressor responses between IL17A −/− and IL-6 −/− background may suggest that there may be compensation for IL-6 deficiency via other IL-6 superfamily of cytokines (interleukin-11, leukemia inhibitory factor, oncostatin-M, cardiotropin, and others) that sustain IL-17 cells and the pressor response.
The TGFBR2 R460C mutation is an activating receptor mutation, producing both tonic TGFβ pathway stimulation 51 and lymphocytic inflammation. 3 This tonic TGFβ signaling is shared by the well-established Marfan FBN1 mutation, a mutation that releases latent TGFβ from the extracellular matrix. Currently, there is evidence that TGFβ and Ang II cross talk plays an important role in vascular pathology. For example, the pathology induced by TGFβ signaling in Marfan disease is significantly attenuated by Ang II antagonism. 52 We, therefore, suspect that pathology in patients with TGFBR2 R460C mutation may be, in part, the consequence of Ang II-IL6 signaling. Our findings for Th17 cell accumulation in these patients suggest that investigation of the Ang II-IL6-Th17 pathway may be further warranted.
In summary, our data suggest that the Th17-IL-17 axis, which is regulated by IL-6-STAT3 signaling, is an important effector arm of Ang II-mediated vascular inflammation. It functions upstream of monocyte/macrophage activation and is independent of Ang II pressor response. Finally, the data indicate that the Th17-IL-17 pathway has direct correlates in human aortic aneurysms and dissections.
